EOLS vs LIN · rev $266.3M vs P/E 34, rev $33.99B
Evolus Inc (EOLS) versus Linde plc Ordinary Shares (LIN) — a side-by-side from cached financials, not a winner call.
Evolus Inc (EOLS) is a drug manufacturers - specialty & generic company listed on US.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Latest reported EOLS revenue for 2024-12-31 was $266.3M. Net income was -$50.4M. Revenue was up 31.8% from 2023-12-31 to 2024-12-31. EOLS currently screens at market cap $597.0M.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
EOLS currently screens at market cap $597.0M. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Not investment advice. Open the EOLS and LIN stock pages for the full models.
Not investment advice.